Northfield reports its oxygen carrier helps islet cell function in animal transplants

New York, July 27 - Northfield Laboratories Inc. said that a study using its hemoglobin-based oxygen carrier found improved islet cell function and transplantation outcomes in small animals.

The study, carried out by a team led by Jose Oberholzer, director of cell and pancreas transplantation at the University of Illinois at Chicago, used a specially formulated version of Northfield's oxygen carrier.

Research has demonstrated that islet cell transplantation can reduce or eliminate the need for insulin in some diabetic patients, the company noted.

The latest findings were presented at the World Transplantation Congress in Boston.

Northfield is an Evanston, Ill., company developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.